Phase 2 N=30 Topical Treatment of Under Eye Dark Circles and Swelling
Edema
Primary: Number of Participants Who Showed Improvement in Under Eye Swelling and Dark Circles Relative to Baseline Per Intervention — 0; 0 participants — p==1
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1,197 SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)…
Phase 2 N=15 Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
Chronic Plaque Psoriasis
Primary: Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores
Phase 2 N=200 Effect of Paracetamol on the Common Cold
Common Cold
Primary: Breathing Scores Post 15 Minutes — 0.83; 0.11 Score on a Scale — p=<0.0001
Phase 2 N=207 Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride
Pneumonia
Primary: Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the mITT Population — 60; 58; 59; 7…
Phase 2 N=41 Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Breast Cancer
Primary: Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat…
Phase 2 N=9 Acitretin and Etanercept in Psoriasis
Psoriasis
Primary: Percent of Patients Achieving PASI 75 at 6 Months After the Addition of Acitretin Therapy — 12.5 percent
Phase 2 N=405 A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
Acute, Uncomplicated Human Influenza
Primary: Time to Alleviation of Symptoms (Kaplan-Meier Estimate) — 106.9; 91.1 hours — p=0.222
Phase 2 N=125 A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Chronic Plaque-type Psoriasis
Primary: Percentage of Participants of Reponders of Psoriasis Area and Severity Index (PASI) 75 Achievement at Week 13 — 3.4; 19.2; 57.1; 81.5 percentage of participants
Phase 2 N=66 Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer
Breast Neoplasms
Primary: Clinical Benefit Rate (CR Plus PR Plus SD) — 0; 0; 3; 1 participants
Phase 2 N=29 Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Change in D-dimer — 478.8; 260.1 ng/mL
Phase 2 N=97 A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With Documented CR, CRi, or PR at the End of Induction Treatment — 82.4 percentage of participants — p=0.0008
Phase 2 N=19 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
Cervical Adenocarcinoma · Cervical Adenosquamous Cell Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Objective Response Rate (PR or CR) — 0 percentage of evalubale patients
Phase 2 N=21 A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
Prostate Cancer · Metastatic Castrate Resistant Prostate Cancer
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 Given Every Two Weeks. — 20 mg/kg every 2 weeks
Phase 2 N=7 Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Pancreatic Adenocarcinoma · Recurrent Pancreatic Carcinoma · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Progression-free Survival — 2.5; 4.0 months — p=0.15